Section A -Research paper

FORMULATION AND ESTIMATION OF ATOMOXETINE HCL FOR BUCCAL DRUG DELIVERY SYSTEM

[1]Sushma Maratha, [2]Mohit Chadha, [3]Vishal Garg, [4]Talluri Srinivasa Rao [5]Jitendra Kumar, [6]Avinash Joriya, [7]Yogita Akash Shinde, [8]Ujash kumar Shah

[1]Assistant Professor SGT College Of Pharmacy SGT University Gurugram, 122505

[2]Assistant Professor Baba Farid College Of Pharmacy Mor Karima , Mullanpur, Ludhiana, Punjab, 142023

[3]Professor & Principal Jaipur School of Pharmacy Maharaj Vinayak Global University Dhand Tehsil Amber Jaipur Delhi NH 11 C Jaipur Rajasthan 302028

[4]Principal, Sankar Reddy Institute Of Pharmaceutical Sciences, Andhrapradesh, 523370

[5]Head of Department, Maa Sharda Pharmacy College Ayodhya, Chikhari Harringtonganj, Ayodhya, Uttar Pradesh, 224208

[6]Associate Professor, Maa Sharda Pharmacy College Ayodhya, Chikhari Harringtonganj, Ayodhya, Uttar Pradesh, 224208

[7]Assistant Professor, Vishwakarma University School of Pharmacy, Kondhwa, Pune, Maharashtra, 411048

[8]Faculty of Pharmacy, Nootan Pharmacy College, SK campus, Sankalchand Patel University, Visnagar, Mehsana, Gujarat.384315

Corresponding Author

Jitendra Kumar,

Head of Department, Maa Sharda Pharmacy College Ayodhya, Chikhari Harringtonganj, Ayodhya, Uttar Pradesh, 224208

DOI:10.48047/ecb/2023.12.si4.699

Abstract

The atomoxetine hydrochloride-based administering tablet concentrated on contained tamarind seed polysaccharide, guar gum, PVP, magnesium stearate, and fine polished cellulose particles. In a short report, the energizer atomoxetine hydrochloride (atomoxetine) expanded the rate of self-destructive ideation in youngsters and teenagers with consideration deficiency/hyperactivity jumble. Gotten and considered. The lengthy delivery tablets contained tamarind seed polysaccharide in addition to guar gum, PVP, magnesium stearate, and MCC. Guar gum and tamarind seed polysaccharide, two different drug polymers, were used to prepare auxiliary discharge grid tablets containing atomoxetine hydrochloride. Qualities such as surface pH, collapse resistance, flatness and moisture content, article homogeneity, weight change, in vitro drug distribution and strength were evaluated. Oral fixation was performed using the most

common dissolvable projection method. The created buccal fix demonstrated a notable buccal fix by sticking to fantastic type of patches characteristics in the results. They've all seen incredible goodness because of the use of polymers.

Keywords: Formulation, Estimation, Atomoxetine, HCL, Buccal Drug, Delivery, System

1. Introduction

One of the likely routes for conventionally large, hydrophilic, unsound proteins, oligonucleotides, polysaccharides, and traditional small medication particles is the buccal route. The treatment of the oral depression might be localized or systemic. Treatment for oral illnesses, dental caries, mouth ulcers, and stomatitis are examples of community treatment. The buccal route is particularly noteworthy for the structure of proteins and peptides as well as the systemic transport of tiny atoms that are exposed to initial pass digestion. The bioadhesive properties of certain polymers that harden upon hydration are used in mucoadhesive drug delivery systems to concentrate drugs in specific areas of the body for long periods of time. Materials that normally adhere tightly to the mucin/mucosal layer of the natural membrane are called 'mucoadhesives'.

The introduction of new, innovative drug delivery systems has superseded traditional methods of medication organization such oral, intramuscular, and intravenous. The systemic and local effects of medication distribution via buccal route make it a desirable method. When compared to an oral course, it has a number of advantages. These advantages include avoiding first pass digestion, as well as the availability, sensible patient acknowledgment, consistency, and the option to remove the measuring framework anytime desired. The human buccal mucosa is made up of a lamina propria, a submucosa, a storm cellar film, and an externalmost layer of defined squamous epithelium. The significant porous barrier for hydrophilic and polar saturates is the epithelium. Atomoxetine Hcl is a potent inhibitor acting on neither presynaptic nor epinephrine carriers, with negligible bias towards other monoamine carriers or receptors. After oral administration, atomoxetine Hcl is heavily ingested, with the peak plasma concentration occurring 1 to 2 hours later. By taking into account the aforementioned considerations and its low restorative component (10-100mg), it is the best option for the development of buccal medication delivery systems.

Many medications are administered via the buccal route, which has several disadvantages including presystemic digestion or first pass liver digestion, gastrointestinal disturbances, and catalyst annihilations. Courses were created to address these issues, including specific intranasal, buccal, transdermal, and pulmonary courses. These courses transport the drug through the circulatory system and prevent presystemic digestion. The constant stream of helping professionals through mucoadhesive prescription drug delivery systems has become incredibly attractive over time. Buccal provision lacks the appearance of being rational because it portends the completion of an unpredictable preservation or other possible related process. has been established as The ability to maintain the developmental system in a particular location for long periods of time is of great importance for the two neighboring regions, as is the bioavailability of the head solution. Lipids, commercially available or manufactured polymers have been used to reliably deliver drugs in a monitored, regulated or targeted manner and to redesign drug uptake

through the oral mucosa to manage bioavailability and healing outcome. It is necessary to use various substances, including and so on. Already used. The buccal mucosa creates a significantly softer environment for absorption of sedatives. Sustained-release mucoadhesive devices may reduce drug efficacy by monitoring pharmaceutical obsession between healthy and unhealthy levels. Both the mucoadhesive properties of the Bio-Stick polymer and the medium in which it acts are available. Chitosan is one of the regularly utilized normal polymers. Chitosan is produced using glucosamine and N-acetyl glucosamine tracked down in mammalian tissues. It is a biodegradable, biocompatible, non-disastrous polymer. Similar to cross area shaping cutoff points, this polymer's film is taken into account. Chitosan is widely used for its entry-enhancing and protein inhibitor characteristics. Two strategies have been introduced to help with buccal maintenance. By modifying the physicochemical features of the drug, it was possible to extend the passage of the prescription through the buccal layer and avoid having the medicine contaminated by synthetic substances. The rectal, vaginal, and ocular mucosa all provide unique advantages, but due to the weak patient suitability associated with these concerns, they are placed aside for peripheral applications rather than the core drug association. Spit swallowing may also prevent the absence of a separate or suspended prescription and, in the end, the necessary departure of the estimates structure.

2. Literature Review

Rifampicin liposomes arranged with drug and lipid proportions by freeze drying were the main focus of Patil et al.'s 2015 study. The pre-arranged powdered liposomes' shape and heated behavior are discussed. Assessment studies for the improved formulation included in vitro disintegration, antitubercular activity, and streamlined features. In comparison to pure drug, the results showed liposome formulations to have higher embodiment proficiency. They conducted in vivo tests in wister rodents using intratracheal instillation of the improved rifampicin powdered liposome formulation and rifampicin unadulterated medication. The results of the pharmacokinetic studies indicated that liposomes are used in a broader manner for medication release.

For macrophages, Zaru Marco et al.'s 2009 study focused on rifampicin lyophilized liposomes. They used soy lecithin and phospholipon-90 with and without cholesterol to organize these liposomes. Liposomal preparations containing cholesterol and phospholipon-90 in molar ratios of 7:1 or 4:1 demonstrated the strongest stability. The effectiveness of the rifampicin liposomal vapor sprayers for nebulization was evaluated. The findings indicated improved safety, and in vitro tests were completed and evaluated in their research on the intracellular activity for Mycobacterium avium complex found in macrophage J774 cells. Pre-arranged liposomes have the ability to prevent Mycobacterium avium complex in contaminated macrophages, according to in vivo tests conducted on rodents for sprayers.

In 2015, Abd El Azim et al. considered and evaluated a liposomal formulation of vitamin B6 for buccal administration. They first assembled vitamin B6 liposomes before forming them into a mucoadhesive film. Sodium carboxy methyl cellulose and hyproxy propyl methyl cellulose were used to create films from the pure vitamin B6 and vitamin B6 liposomes. Results showed that

with liposomal films compared to pure plain film, prolonged discharge appeared to last 6 hours. While in vivo mucoadhesive tests are conducted on human subjects, ex vivo mucoadhesion studies are completed using chicken pockets. The transition was less pronounced for liposomal films than for liposomal scattering, according to ex vivo data, and saturation was greater for liposomal films than for the control formulation. Finally, liposomal films were produced, which prevented drug discharge and increased penetration.

Exemestane liposomes were studied by Sakshi and Smita in 2014 to improve bioavailability. Using the Box-Behnken Plan, they organized the liposomes according to the film hydration method. Buccal patches were also developed for the most recent category of sophisticated liposomes. Finally, they closed factorial plan advances for the best formulations, and they discovered that buccal patches made of liposomes could kill the effects of the first pass.

Curcumin liposomes organized with common, produced bioadhesive polymers were tested and evaluated by Berginc et al. in 2014. They developed an in vitro model that contains vaginal fluid to mimic similar conditions to the vaginal environment in order to focus on in vitro examinations. They enhanced with glycoproteins and used cow-like mucosa to test the strength of the bioadhesion. When compared to the control, the results showed greater curcumin penetration through cow-like bodily fluid. Finally, the polymer covering's bioadhesive nature has expanded, and those liposomes may now be directed intravaginally.

Alsarra et al. (2008) focused on developing mucoadhesive nasal gel for mucosal delivery of acyclovir liposomes. For liposomal formulations, the results showed ideal entanglement effectiveness with bioavailability. Finally, the acyclovir liposomes and gel were closed, and the nasal pit showed delayed contact and direct assimilation.

3. MATERIALS AND METHODS

3.1. Requirements for Experiments

Table 1: requirements list

S. No.	Chemical Supplier Category
1.	Atomoxetine HCI CDH Laboratory, New Delhi API
2.	Eudragit L 100 Zim Laboratories Limited, Kalmeshwar, Nagpur
3.	HPMCK 15L, Evonik Degussa India Private Limited, Mumbai
4.	Propylene Glycol 400, CDH Laboratory, New Delhi
5.	Ethanol, CDH Laboratory, New Delhi

- **Preformulation Studies**

Pre-formulation focuses on the work to be completed before prescribing improvement begins and one of the main objectives of the review is to provide a reliable , to provide or facilitate safe, effective remediation methods.

- **Atomoxetine characteristics**

Atomoxetine Hcl that has been micronized has undergone actual testing for preformulation evaluation.

- **Identification of Drug**

The drug and excipients were identified and assessed using the Fourier change infrared spectroscopy (FT-IR) technique. A Perkin-Elmer model was used to record the FT-IR range using drug KBR pellets.

- **FT-IR spectroscopy procedure**

FT-IR spectroscopy was utilized to investigate the drug and many stretches between C-H, C-N and C-O were recognized. The filtering system was treated with the medication's pure form. To record the IR spectra, potassium bromide was added to the medicine. The useful groups in FT-IR spectra are topped for attributes.

- **Protocol for Drug – Excipients Compatibility Studies**

Studies on the similarity between drugs and excipients are typically important for selecting appropriate additional ingredients or excipients to support a medication formulation. Through the course of this review, various organoleptic characteristics were noted. The formulation's stability is guaranteed by the similarity test for drug excipients. For pure constantly used medications with excipients in a specific ratio, the various filtering was finished.

Kinetic agents were mixed with potassium bromide and spectra were recorded. As above, excipients and potassium bromide 2:2 ratio for acquiring spectra The FT-IR spectrum of atomoxetine with various excipients was also produced, and the FT-IR range of atomoxetine was compared. For atomoxetine, the peak of the spectrum could shift or disappear.

- **Procedure**

In the ratio shown in table 0.0, atomoxetine was mixed with the other excipients used in the concentrate. The mixture was then filled into glass vials with a low-thickness polyethylene plug that had openings in it and subjected to prolonged exposure to various temperatures, including room temperature, 60 °C, and 2 °C. The mixtures were checked for real change and moisture content after the allowed time had passed.

- **Proposed Experiment Formulations**

Different drug centralizations, particular polymers for improved bioavailability, and the introduction of dynamic drug fixing were all used in the formulation's preparation.

- **Required quantity of Ingredients**

The amount of fixes required for the creation of vital groups is shown in the following table.

Table 2: Ingredients required preparing the test batches

Sr. No.	Ingredients	Approx. Quantity Required
1	Atomoxetine Hcl	0.014 kg
2	Edragit L 100	1.140 kg
4	HPMCK 15M	1.140 kg
5	Propylene Glycol	0.514 Ltr.
7	Ethanol	2.640 Ltr.

- **Various excipients ratios (F1-F5)**

The various excipients quantities used to make buccal patches are listed in the above table.

Table 3: with different excipients ratios, F1 to F5.

Sr. No.	Ingredients	Unit Formula (mg or ml/tablet)				
		F -1	**F – 2**	**F - 3**	**F - 4**	**F - 5**
1.	**Atomoxetine Hcl (mg)**	30	30	30	30	30
2.	**Propylene Glycol 400 (ml)**	0.4	0.4	0.4	0.4	0.4
3.	**HPMCK 15 (mg)**	50	45	50	55	60
4.	**Edragit L 100 (mg)**	60	55	50	45	65
5.	**Ethanol (ml)**	2	2	2	2	2
Net Wt. / Tab. In mg		130	130	130	130	130



Figure 1: with different excipients ratios, F1 to F5.

- **Drug- Excipients compatibility study protocol**

The proportion of drug excipients that are comparable is shown in the accompanying table.

Table 4: Drug Excipients Similarity Study Convention

S. N.	Ingredients	Drug: Excipients Ratio
1	Edragit L 100	2:2
2	HPMCK 15L	2:2
3	Propylene Glycol	2:2
4	Ethanol	2:2

- **Formulation Development**

The content and methods used to create the buccal patch and the corresponding final decision evaluation limits are described in the next section.

- **How to make an atomoxetine buccal patch**

Overall, five formulas were arranged in various ways. The several formulations for Atomoxetine Buccal Patches are listed in the table below.

The following were the methods used in the planning of buccal patches:

- **Making atomoxetime buccal patches using the solvent casting method**

In order to dissolve in ethanol, Eudragit L100 and HPMCK15M are presented in precise amounts and are stirred with attractiveness to ensure proper arrangement. As a pervasion enhancer and plasticizer, respectively, atomoxetine (40 mg), propylene glycol, and tween 80 are added to the aforementioned scattering while continuously mixing. The petri plate is filled with the uniform scattering. Reversing the cut channel over the patches slows down the dissolvable rate of disappearance. The dried movies are removed after 24 hours and stored in desiccators to prevent moisture.

3.2. Evaluation parameters

- **Weight variation**

Each buccal patch has a different weight limit, so it is possible to compare them and make sure they are all subject to the same limits.

- **Flatness**

Each repair will be evaluated by both sides for levelness. Each fix will be evaluated by both sides for evenness. Each strip's length is estimated, and there may be some variation due to the consistency in levelness taking into account narrowing, with 0% tightness equal to 100% evenness.

- **Folding strength**

For the buccal repair, the collapse strength is physically estimated. A piece of the movies is sliced in half and repeatedly collapsed in the same place until it is split.

- **Moisture level**

Each patch is weighed separately before being dehydrated for a full day. The patches are examined once more until a steady weight is attained. Based on the contrast between the underlying and stable final loads, dampness content is determined in rate using the following equation:

$$\textbf{Percentage moisture absorbed} = \frac{\textbf{Final weight} - \textbf{Intial weight}}{\textbf{Intial weight}} \textbf{X 100} \qquad (1)$$

- **Drug content analysis**

In a pH 7.4 PBS solution, a tiny patch of fix is cut into pieces. The polymer solvent is then created by adding easily dissolved ethanol, and any additional volume is then prepared up to 100 ml with pH 7.4 PBS. The mixture is then divided into 10 ml and 1 ml is taken out and diluted once more. The arrangement's absorbance is calculated at frequency 270 nm, and fixation is determined.

- **Stability studies**

To complete the security investigation, the improved formula is kept on a double-page spread, covered with aluminum foil and placed inside. Finally, heat it up and leave it at room temperature for a month. The movies are examined for their appearance, dividing time, and drug content by adhering to the aforementioned norms and are taken at various time stretches such as 0 to fourth week.

4. RESULTS AND DISCUSSION

4.1. Description of the Active Drug

The dynamic medicine was put through the standard test to evaluate it for various boundaries, and if needed, the results are listed in the accompanying table.

Table 5: Results of Atomoxetine Hcl analysis

Test	Specification	Observation	Conclusion
Description	White color powder	White color powder	Complied
Odor	Odorless	Odorless	Complied
Solubility	Highly soluble in water	Practically Highly soluble in water	Complied
	Partially soluble in methanol	Practically partially soluble in methanol	Complied

4.2. Study of the FT-IR Spectrum for Drug Excipients

4.2.1. Spectrum of atomoxetine HCL in FT-IR

FT-IR convert's erroneous data into real range using the Fourier transform mathematical cycle. FT-IR innovation is utilized to get the infrared scope of entrance or maintenance for fuel testing. The 600–4000 cm-1 infrared digestion range Range data in the electronic programming of spectroscopy will be used to determine which sub-nuclear groups will triumph in the model.

4.2.2. Preparation of 0.1 N HCL, 100 g/mL atomoxetine stock solution (IP, 2018)

The drug, atomoxetine, was totally broken up in 100 mL of 0.1 N HCl.

4.2.3. Calculation of the maximum absorption, or max

By filtering drug testing at 270 nm or below, the maximum absorbance (max) of atomoxetine was determined using a UV (apparent spectrophotometer), and spectra were found.

4.3. Assessment of Buccal Patches

4.3.1. Surface pH analysis

The surface pH of the buccal fix is shown in the adjacent table. The sophisticated pH meter of the research facility setup was used to measure the pH.

Table 6: pH of the surface of the prepared buccal patch

Formulation	Time (checked after)	pH
F1	1 hour	6.3
F2	1 hour	5.7
F3	1 hour	5.7
F4	1 hour	6.2
F5	1 hour	7.6



Figure 2: pH of the surface of the prepared buccal patch

4.3.2. Folding endurance

The table that follows demonstrates that formulas F1 through F5 have the ideal amount of collapsing power.

Table 7: Folding strength

Formulation	Folding endurance
F1	20
F2	23
F3	26
F4	30
F5	24



Figure 3: Folding strength

4.3.3. Swelling index study

The accompanying table displays the formulas' expanding power (F1–F5).

Table 8: Increasing force

Formulation	Weight (g)	Weight after swelling
F1	0.73	0.82
F2	0.64	0.73
F3	0.58	0.67
F4	0.68	0.74
F5	0.62	0.74



Figure 4: Increasing force

4.3.4. Time of in-vitro release measurement

The accompanying table discusses the in-vitro discharge time.

Table 9: total percent of drugs released

Time (hr)	Cumulative % drug release				
	F1	**F2**	**F3**	**F4**	**F5**
1	5.13 ± 0.54	5.80 ± 0.43	6.40 ± 0.38	6.74 ± 0.52	6.24 ± 0.26
2	7.20 ± 0.42	7.35 ± 0.36	7.52 ± 0.46	8.32 ± 0.42	8.42 ± 0.35
3	22.31 ± 0.63	22.62 ± 0.68	20.80 ± 0.52	22.63 ± 0.71	22.23 ± 0.37
4	24.15 ± 0.52	24.62 ± 0.46	24.82 ± 0.42	23.26 ± 0.52	24.23 ± 0.73
5	26.72 ± 0.50	26.32 ± 0.40	25.78 ± 0.62	26.38 ± 0.41	26.20 ± 0.37

4.3.5. Muco-adhesive strength measurement

Table 10: Muco adhesion power

Preparation	**F1**	**F2**	**F3**	**F4**	**F5**
Muco-adhesive Strenght (G)	2.32	2.82	3.10	2.43	3.24



Figure 5: Muco adhesion power

4.3.6. Folding endurance

The buccal fix described above demonstrated unwavering collapsing endurance on the part of the fix. It might very well be kept under strong areas for a little stress and thrush. It is stronger and more durable in terms of security due to its improved collapsing endurance.

4.3.7. Swelling index study

The above-mentioned buccal repair showed a significant amount of hypertrophy. List expansion is crucial to understanding the true properties of buccal healing. It declares that the spit delivery system improves drug absorption and breakdown rates. This enables the formulation to have a good bioavailability in the systemic distribution once it is retained.

4.3.8. Time for in-vitro release

The formulation's in-vitro discharge rate in the buccal fix was astonishingly quick. Additionally, it guarantees the products' uniformity. This formulation's property is crucial for the formulation to be shown as quick delivery oral movies at the appropriate time. Delivery of the buccal fix depends on the consistency of the fix and a favorable setting for medication dispersion and breakdown.

4.3.9. Muco adhesive power

Because different muco adhesive polymers were joined together, the formed fix's muco adhesive strength demonstrated a striking power. It also aids in strengthening the formulation's soundness. The introduction of Dynamic Drug Fixing (Programming interface) with multiple polymers and excipients in a separate dissolvable medium also makes it work.

4.3.10. Stability study

The fix's structural strength was tested. It demonstrated greater formulation strength and may have shown major weaknesses when excipients were used. A formulation's consistency is the most crucial factor to evaluate because it indicates the entire life (time span of usability) of the thing computed under ideal circumstances. Due to the use of top-notch polymers in the enhancement of the item (buccal repair), it was discovered to be steady.

5. Conclusion

One of the organization's optional courses was the development of bioadhesive buccal medication delivery for tizanidine hydrochloride tablets in order to delay discharge and prevent first-pass effects. These formulations also reduce the need for routine organization and improve patient consistency. Supported buccal medication administration is achieved by combining sodium carboxymethyl cellulose and hydroxypropyl methylcellulose K4M. It was thought that the in vitro drug discharge wasn't Fickian. The findings unequivocally support the hypothesis that sodium deoxycholate's effects on par cellular and transcellular pathways contributed to the growth of the pervasion. Abstract borders and a muco adhesive style of acting were deemed acceptable by solid human professionals.

Atomoxetine buccal patches were created to have enough mechanical strength to withstand handling, packing, delivery, stockpiling, and transportation. The tablets were set up according to the rules' specified placement. Formulation F1 displayed a rapid decomposition and disintegration profile. Drug breakdown also affects bioavailability and formulation's curative effects. The new formulation was taken into account for security evaluations. Buccal patches of atomoxetine were consistent and stable during a variety of typical ecological storage conditions, according to findings from soundness investigations. The mouth-dissolving film of atomoxetine HCl was described in an excellent manner. F2 was picked as a result of its high evaluation scores and exceptional mechanical qualities. It is also a suitable replacement for traditional atomoxetine HCl tablets or containers. Numerous experts have conducted numerous studies to develop rapidly evaporating oral films that will increase the effectiveness of medications.

References

1. Alsarra, I.A., Hamed, A.Y., Alanazi, F.K., Acyclovir Liposomes for Intranasal Systemic Delivery: Development and Pharmacokinetics Evaluation, Drug Delivery, Vol. 15, No. 5, pp. 313-21, (2008).

2. Abd El Azim, H., Nafee, N., Ramadan, A., Khalafallan, N., Liposomal Buccal Mucoadhesive Film for Improved Delivery and Permeation of Water-Soluble Vitamins, International Journal of Pharmaceutics, Vol. 488, No. 1-2, pp. 78–85, (2015).

3. Berginc, K., Suljaković, S., Škalko-Basnet, N., Kristl, A., Mucoadhesive Liposomes as New Formulation for Vaginal Delivery of Curcumin, European Journal of Pharmaceutics and Biopharmaceutics, Vol. 87, No. 1, pp. 40-46, (2014).

4. Davies J. and A. Ingham, "An in-vitro–in-vivo model for the transdermal delivery of cholecalciferol for the purposes of rodent management," International Journal of Pharmaceutics, 2020; 487(1-2): 101–109.

5. Gadwani Bina, Amber Vyas. Synthesis, "Characterization and Application of Epichlorohydrin-Beta-Cyclodextrin polymer," Colloids and Surfaces B: Biointerfaces, 2014; 130: 130-137.
6. Hanif Muhammad, Muhammad Zaman, Vesh Chaurasiya, "Polymers used in buccal film: a review," Designed Monomers and Polymers, 2015; 18(2): 105-111.
7. Lakshmi P. K, Malavika P, Vidya K, "Formulation and Evaluation of Oral Films of Atomoxetine Hydrochloride," International Research Journal of Pharmacy, 2018; 9(9): 105-109.
8. Mamatha Tirunagari, Syed Ahmed, Anitha Nandagopal, "Development, Formulation and Evaluation of Atomoxetine Oral Films." International Journal of Drug Delivery and Research, 2014; 6(2): 46-51.
9. N. G. Raghavendra Rao, Sunil Firangi, Keyur Patel Formulation and in-vitro evaluation of mucoadhesive buccal patches containing zolmitriptan using gel forming polymers Pelagia Research Library Der Pharmacia Sinica, 3 (1), 2012, 47-57
10. NavneetVerma and Pronobesh Chattopadhyay Preparation of Mucoadhesive Patches for Buccal Administration of Metoprolol Succinate: In Vitro and In Vivo Drug Release and Bioadhesion Tropical Journal of Pharmaceutical Research February 11 (1), 2012, 9-17
11. P. Sandhya, Nazera Tazyeen, M. Sunitha, M. Sirisha, R. Sunil Formulation And Evaluation Of Buccal Films Of Ketorolac Tromethamine Journal of Global Trends in Pharmaceutical Sciences Volume 4, Issue 3, pp -1184-1192, July-September 2013
12. Patel Parth S., Ashish M., Parmar Nilang, S. Doshi, Hardik V. Patel, Raxit R. Patel, Chetan Nayee, "Buccal Drug Delivery System: A Review", International Journal of Drug Delivery and Research, 2013; 5(3): 35-48.
13. Patil, J.S., Devi, V.K., Devi, K., Sarasija, S., A Novel Approach for Lung Delivery of Rifampicin-Loaded Liposomes in Dry Powder Form for the Treatment of Tuberculosis, Lung India, Vol. 32, No. 4, pp. 331-338, (2015).
14. Prasanth V.V, Mamatha. Y, Selvi Arun Kumar, Sam T Mathew, Abin Abraham Formulation and Evaluation of Mucoadhesive Buccal Patches of Aceclofenac Scholars Research Library Der Pharmacia Lettre, 4 (1), 2012, 297-306
15. Reddy Yella Thirupathi, Rohit Saraswat, Reddy Sunil, "Design and Characterization of Buccal Patches of Atomoxetine", International Journal of Pharmaceutical Sciences Review and Research, 2019; 56(1): 96-102.
16. Sakshi, G., Smita, B., Formulation and Optimization of Liposomal Delivery Vehicle of an Anti-Cancer Drug Exemestane by BOX-Behnken, Design Journal of Pharmacy Research, Vol. 8, No. 7, pp. 937-941, (2014).
17. Shalini Mishra, G. Kumar, P. Kothiyal Formulation and Evaluation of Buccal Patches of Simvastatin by Using Different Polymers The Pharma Innovation ISSN: 2277- 7695 CODEN Code: PIHNBQ Vol. 1 No. 7 2012
18. Tian Ye, Y. Sun, X. Wang, G. Kasparis, S. Mao, "Chitosan and its derivatives-based nano-formulations in drug delivery," Nan biomaterials in Drug Delivery, 2016; 9: 515-572.

19. Verma Surender, Mahima Kaul, Aruna Rawat, Sapna Saini, "An Overview On Buccal Drug Delivery System, International Journal of Pharmaceutical Sciences And Research, 2017; 2(6): 1303-1324.

20. Zaru, M., Sinico, C., De Logu, A., Caddeo, C., Lai, F., Manca, M.L., Fadda, A.M., Rifampicin-Loaded Liposomes for The Passive Targeting to Alveolar Macrophages: In Vitro and In Vivo Evaluation, Journal of Liposome Research, Vol. 19, No. 1, pp. 68-76, (2009).

****